The challenge of latent TB infection

JAMA - Journal of the American Medical Association

Volumn 316, Issue 9, 2016, Pages 931-933

  Blumberg, Henry M ^a,b   Ernst, Joel D ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISONIAZID; RIFAMPICIN; RIFAPENTINE;

CAUSE OF DEATH; CLINICAL OUTCOME; DIRECTLY OBSERVED THERAPY; DRUG SELF ADMINISTRATION; EDITORIAL; FALSE POSITIVE RESULT; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LOW RISK POPULATION; MIXED INFECTION; MORTALITY RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OCCUPATIONAL SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; SCREENING; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS CONTROL; UNITED STATES; COMMUNICABLE DISEASE; TUBERCULOSIS;

COMMUNICABLE DISEASES; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84986880104     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.11021     Document Type: Editorial

References (21)

1. World Health Organization. Global Tuberculosis Report, 2015. 20th ed. Geneva, Switzerland:World Health Organization; 2015.
2. Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ. Leveling of tuberculosis incidence-United States, 2013-2015. MMWR Morb Mortal Wkly Rep. 2016;65(11):273-278.
3. Centers for Disease Control and Prevention. Fact Sheet: Trends in Tuberculosis, 2014. http://www .cdc.gov/tb/publications/factsheets/statistics/tbtrends-2014.pdf. Accessed July 20, 2016.
4. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, BerryMP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475-527.
5. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, Horne DJ, Kao TC. The prevalence of latent tuberculosis infection in the United States [published online February 11, 2016]. Am J Respir Crit Care Med. 2016. doi:10.1164/rccm.201508-1683OC.
6. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000; 49(RR-6):1-51.
7. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54(RR-12):1-81.
8. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563-1576.
9. Kahwati LC, Feltner C, Halpern M, et al. Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2016 .10357.
10. US Preventive Services Task Force. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA. doi:10.1001/jama.2016.11046.
11. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127-2135.
12. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva, Switzerland:World Health Organization; 2015.
13. Zak DE, Penn-Nicholson A, Scriba TJ, et al; ACS and GC6-74 cohort study groups. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387 (10035):2312-2322.
14. California Department of Public Health. California Tuberculosis Risk Assessment. https://www.cdph.ca.gov/programs/tb/Documents/TBCB-CA-TB-Risk-Assessment-and-Fact-Sheet.pdf. Accessed July 20, 2016.
15. Centers for Disease Control and Prevention. Sample TB Risk Assessment Tool. http://www.cdc .gov/tb/publications/ltbi/appendixa.htm. Accessed July 20, 2016.
16. Agoritsas T, Courvoisier DS, Combescure C, Deom M, Perneger TV. Does prevalence matter to physicians in estimating post-test probability of disease? a randomized trial. J Gen Intern Med. 2011; 26(4):373-378.
17. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005; 54(RR-17):1-141.
18. Dorman SE, Belknap R, Graviss EA, et al; Tuberculosis Epidemiologic Studies Consortium. Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77-87.
19. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, et al; Tuberculosis Epidemiologic Studies Consortium (TBESC). Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis. 2015;19 (1):31-38.
20. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.MMWRMorb Mortal Wkly Rep. 2011;60(48):1650-1653.
21. Belknap RBA, Holland D, Feng PJ, et al. Adherence to once-weekly self-administered INH and rifapentine for latent TB: iAdhere (Abstract 827LB). Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 23-26, 2015; Seattle,WA.